Inhibition of lysophosphatidic acid receptor 1–3 deteriorates experimental autoimmune encephalomyelitis by inducing oxidative stress

Jong Hee Choi¹, Jinhee Oh¹, Min Jung Lee¹, Hyunsu Bae², Seong-Gyu Ko³, Seung-Yeol Nah⁴ and Ik-Hyun Cho¹,5*

Abstract
Background: Lysophosphatidic acid receptors (LPARs) are G-protein-coupled receptors involved in many physiological functions in the central nervous system. However, the role of the LPARs in multiple sclerosis (MS) has not been clearly defined yet.

Methods: Here, we investigated the roles of LPARs in myelin oligodendrocyte glycoprotein peptides-induced experimental autoimmune encephalomyelitis (EAE), an animal model of MS.

Results: Pre-inhibition with LPAR1–3 antagonist Ki16425 deteriorated motor disability of EAElow. Specifically, LPAR1–3 antagonist (intraperitoneal) deteriorated symptoms of EAElow associated with increased demyelination, chemokine expression, cellular infiltration, and immune cell activation (microglia and macrophage) in spinal cords of mice compared to the sham group. This LPAR1–3 antagonist also increased the infiltration of CD4⁺/IFN-γ⁺ (Th1) and CD4⁺/IL-17⁺ (Th17) cells into spinal cords of EAElow mice along with upregulated mRNA expression of IFN-γ and IL-17 and impaired blood–brain barrier (BBB) in the spinal cord. The underlying mechanism for negative effects of LPAR1–3 antagonist was associated with the overproduction of reactive oxygen species (ROS)-generating nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) 2 and NOX3. Interestingly, LPAR1/2 agonist 1-oleoyl-LPA (LPA 18:1) (intraperitoneal) ameliorated symptoms of EAEhigh and improved representative pathological features of spinal cords of EAEhigh mice.

Conclusions: Our findings strongly suggest that some agents that can stimulate LPARs might have potential therapeutic implications for autoimmune demyelinating diseases such as MS.

Keywords: Lysophosphatidic acid receptors, Experimental autoimmune encephalomyelitis, Reactive oxygen species, NADPH oxidase

Background
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune, and demyelinating disease of the central nervous system (CNS). Specific symptoms of MS can include double vision, blindness in one eye, muscle weakness, trouble with sensation, stiffness, and spasms. While the exact etiology of MS is unclear, it is thought to be due to a combination of genetic and environmental factors such as infectious agents [1–3]. The pathology of MS is related to demyelination, axonal and oligodendrogial loss, reactive astrocytes or gliotic scar formation, disruption of the blood–brain barrier (BBB), and infiltration of peripheral immune cells, including lymphocytes and macrophages [4, 5]. Unfortunately, complete cure for MS is currently
unknown. MS patients usually take intravenous steroids, anti-inflammatory medications (corticosteroids), disease-modifying drugs, and so on, to improve their function after an attack and prevent new attacks [2, 3, 6]. However, these treatments have limited efficacy. In addition, adverse drug reactions such as irritation at the injection site, influenza-like syndrome, and heart palpitations might occur during long-term medication [3, 6]. Therefore, it is essential to research and develop innovative medications for delaying the onset of MS or forestalling its progression.

Oxidative stress is characterized as an imbalance between the production of reactive oxygen species (ROS) and the antioxidant capacity of the cell [7, 8]. ROS can induce mitochondrial DNA mutations, damage the mitochondrial respiratory chain, alter membrane permeability, and influence intracellular Ca\(^{2+}\) homeostasis and mitochondrial defense systems [7, 8]. Normally, ROS are generated by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) and eliminated from cells by reducing agents or by enzymatic reactions to maintain homeostasis in the body [9]. ROS at low physiological intracellular levels can promote cellular growth and survival signaling pathways, whereas ROS at higher levels can induce growth arrest and cellular apoptosis or senescence. Interestingly, excessive ROS play a crucial role in various pathologic mechanisms underlying MS and EAE [7, 8]. In the early stage of lesion (demyelination) formation, ROS may lead to BBB disruption and accelerate transendothelial migration of peripheral immune cells such as T cells and macrophages into the CNS [7, 8]. Consequently, ROS play a critical role in lesion persistence or deterioration in MS and EAE by continuing worsening demyelination and inducing axonal and oligodendrocyte damage [7, 8]. Thus, antioxidants that can inhibit excessive generation of ROS or escape harmful activities of ROS might be good therapeutics for preventing and treating MS and EAE [7, 8]. Currently, accumulated evidences have suggested that ROS are generated by lysophosphatidic acid (LPA) signaling in adipose derived stem cells [10], PC-3 human prostate cancer cells [11], ovarian cancer cells [12], and mouse J774A.1 macrophages [13]. These reports strongly suggest that regulating LPA signaling might influence the pathologic mechanism underlying MS and EAE.

LPA is a major lysophospholipid that acts as both a minor membrane component and an extracellular signaling mediator in numerous organs, tissues, and body fluids [14]. LPA primarily signals via the activation of six cognate G protein-coupled receptors, lysophosphatidic acid receptors (LPARs) 1–5, and atypical LPAR6 [14]. LPARs are differentially expressed in most cell types of central and peripheral nervous tissues. They are involved in many functions of neuronal networks [14]. LPA signaling via LPARs can influence cell survival, cell differentiation, cell proliferation, cell migration, angiogenesis, neurogenesis, and neuroplasticity in normal and abnormal nervous systems [14]. It can stimulate chemotaxis, polarization, motility, and transendothelial migration of immature murine dendritic cells or naive T cells of the immune system into the CNS [15–17]. Interestingly, serum levels of LPAs in MS patients and EAE murine model are decreased compared to those in healthy controls whereas those of LPAs in spinal cords in T cell receptor transgenic mice (relapsing–remitting mice) are increased during symptom-free and recovery intervals of experimental autoimmune encephalomyelitis (EAE) model, a murine model mimicking MS [18]. LPAR2-positive T cells and myeloid cells are diminished in the spleen of EAE mice while its mRNA levels are increased in circulating white blood cells and lumbar spinal cords of EAE mice [18]. These reports strongly suggest that LPARs might be crucial receptors in the pathogenesis of MS and EAE. Although complexities of LPA receptor signaling in neuronal inflammation such as MS and EAE have been demonstrated, they are not well appreciated yet. Here, we explored whether LPAR1–3 antagonist or agonist could regulate motor disability and inflammation in an EAE murine model. Our findings suggest that some agonists for LPAR1–3 might be useful as therapeutics to prevent and treat autoimmune demyelinating diseases such as MS.

**Methods**

**Experimental animals and ethic approval**

The 8- to 9-week-old C57BL/6J female mice (weight, 19–21 g) were purchased from the Narabiotec Co., Ltd. (Seoul, Republic of Korea). Their seed mice originated from Taconic Biosciences Inc. (Cambridge, IN, USA). The mice were allowed free access to the usual standard laboratory food and tap water. The mice were housed under a 12-h light/dark cycle (light on 08:30–20:30) at room temperature (23±2 °C) and humidity (54±15%). Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Kyung Hee University (KHUASP-18-174). Animal treatment and maintenance were carried out in accordance with IACUC guidelines. In this process, proper randomization of laboratory animals and handling of data were performed in a blinded manner in accordance with recent recommendations from an NIH workshop on preclinical models of neurological diseases [19].

**Experimental group and drug treatment**

To investigate the effect of Ki16425, LPAR1–3 antagonist, on EAE\(^{low}\), the experimental group was randomly divided...
into the following groups (n = 5 per group): the Sham [vehicle treatment, s.c. + saline, i.p.], EAE<sub>low</sub> [200 µg of myelin oligodendrocyte glycoprotein (MOG)<sub>35–55</sub> peptide, s.c. + saline, i.p.], EAE<sub>low</sub> + Ki16425 [200 µg of MOG<sub>35–55</sub>, s.c. + 15 and 30 mg/kg of Ki16425, i.p.], and Ki16425 alone groups [vehicle treatment, s.c. + 30 mg/kg of Ki16425, i.p.]. Ki16425, an LPAR1–3 antagonist (Tocris Bioscience, Bristol, UK), was prepared in 5% dimethyl sulfoxide (DMSO)/phosphate buffered saline (PBS) and was administered once daily from onset phase (day 9 after EAE<sub>low</sub> induction; mean score of motor disability, approximately 0.5). To examine the effect of 1-oleoyl-LPA (LPA 18:1), LPAR1/2 agonist, on EAE<sub>high</sub>, the experimental group was randomly divided into the following groups (n = 5 per group): the Sham [vehicle treatment, s.c. + saline, i.p.], EAE<sub>high</sub> [200 µg of MOG<sub>35–55</sub>, s.c. + saline, i.p.], EAE<sub>high</sub> + 1-oleoyl-LPA [200 µg of MOG<sub>35–55</sub>, s.c. + 0.5 and 1 mg/kg of 1-oleoyl-LPA, i.p.], and LPA alone group [vehicle treatment, s.c. + 1.0 mg/kg of 1-oleoyl-LPA, i.p.]. 1-oleoyl-LPA, an LPAR1/2 agonist was dissolved in PBS and administered once daily for 10 days from onset phase (day 8 after EAE<sub>high</sub> induction; mean score of motor disability, approximately 0.5). The same experiments were repeated 3 times.

**EAE induction and motor disability assessment**

Mice were immunized with 100 µl of emulsion containing MOG<sub>35–55</sub> peptide (Sigma, St. Louis, MO, USA) in PBS, 100 µl of complete Freund’s adjuvant (CFA; Sigma), and Mycobacterium tuberculosis extract H37Ra (Mtb) into the hind flank subcutaneously. Mice also received 200 ng of pertussis toxin (Sigma, St. Louis, MO, USA) through i.p. injection on the day of immunization and at 48 h after immunization. EAE was induced by two different methods. The EAE model presenting low scores of motor disability (called EAE<sub>low</sub>) was induced with 200 µg of MOG peptide and 300 µg of Mtb. The EAE model presenting high scores of motor disability (called EAE<sub>high</sub>) was induced with 200 µg of MOG<sub>35–55</sub> and 300 µg of Mtb. These models were used to investigate effects of Ki16425 (LPAR1–3 antagonist) and 1-oleoyl-LPA (LPAR1/2 agonist) on EAE. The same experiments were repeated 3 times. After immunization, mice were observed daily to record scores of motor disability using the following criteria: score 0, no signs; score 1, mild loss of tail tone; score 2, complete loss of tail tone without hind limb paralysis; score 3, complete loss of tail tone and hind limb weakness (abnormal gait); score 4, complete hind limb paralysis; score 5, complete hind limb paralysis and forelimb weakness (or unilateral forelimb paralysis); score 6, quadriplegia, moribund condition; and score 7, death [20–22].

**Cryosections preparation and histopathological staining**

At the peak stage (19–20 days) of neurological symptoms after EAE<sub>low</sub> and EAE<sub>high</sub> induction, mice (n = 5 per group) were euthanized under diethyl ether anesthesia and perfused intracardially with 0.9% saline followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Lumbar spinal cords were removed and cryosections (10 µm thick; n = 3 per spinal cord; 5 spinal cords per group) were prepared as previously described [20–22]. The cryosections were stained with luxol fast blue (LFB) dye and hematoxylin and eosin (H&E) to evaluate demyelination and immune cell infiltration, respectively, as previously described [20–22].

**Quantification of demyelination and cellular infiltration**

To quantify the level of demyelination after LFB staining, demyelinated area and total areas of white matter were measured for three fields per section (3 sections per spinal cord, 5 spinal cords per group) using ImageJ Software (NIH, USA). The final % value for demyelination was presented as mean demyelinated area (µm²) per optical field (at 200× magnification). The level of cellular infiltration after H&E staining was quantified by semi-manually counting the number of total inflammatory cells per optical field using the ImageJ Software. For each group, three fields per section (3 sections per spinal cord, 5 spinal cords per group) were analyzed. The final value was presented as total cell number per optical field. The investigators who performed these tissue investigations were blinded to mouse groups until the end of the experiment after graphs were generated and tissue sections were compared.

**Immunofluorescence and immunohistochemistry evaluation**

Immunofluorescence analysis was accomplished as previously described [20–22]. Briefly, cryosections (10 µm thick; n = 3 per spinal cord; 5 spinal cords per group) from lumbar spinal cords in each group were incubated with rat anti-CD3 (1:500; BD Biosciences, NJ, USA), rat anti-myelin basic protein (MBP) (1:1000; Abcam), anti-ionized calcium binding adaptor molecule-1 (Iba-1) antibody (1:2000; Wako, Osaka, Japan), mouse anti-glial fibrillary acidic protein (GFAP; 1:2000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and/or rat anti-platelet endothelial cell adhesion molecule (PECAM)-1 (1:500; Santa Cruz), mouse anti-albumin (1:500; Santa cruz), and rabbit anti-immunoglobulin G (IgG) (1:500; Abcam), mouse anti-occludin (1:500; Invitrogen, MA, USA), mouse anti-ZO-1 (1:500; Invitrogen) as primary antisera and cyanine 3- and fluorescein-isothiocyanate (FITC)-conjugated mouse/rabbit/rat IgG antibody...
Western blot assessment
At the peak stage (19–20 days) of neurological symp-
toms after EAElow and EAEhigh induction, the lumbar
segments of the spinal cords (n = 3 per group) from
each group were rapidly cropped under diethyl ether
anaesthesia. Western blot analysis was performed by pre-
viously described [20–22] using rat anti-CD3 (1:500; BD
Biosciences), rabbit anti-LPAR1–3 (1:1000; Abcam), rat
anti-MBP (1:1000; Abcam), rabbit anti-Iba-1 (1:1000;
Wako), rat anti-PECAM-1 (1:500; Santa cruz), mouse
anti-GFAP (1:2000; Millipore), rabbit anti-cyclooxygen-
ase (COX)-2 (1:1000; Santa Cruz), rabbit anti-phospho
(p)-nuclear factor-kappa B (NF-kB) NF-kB, p-p38, and
p38 (1:1000; Cell signaling technology), goat anti-4-hy-
droxynonenal (4-HNE) (1:500; Abcam), or horse-rad-
ish peroxidase-conjugated secondary antibodies (1:200;
Vector Laboratories, Burlingame, CA, USA). Anti-glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) anti-
body (1:1000; Cell Signaling Technology) was used as an
internal control for relative protein quantification. Poly-
vinyldene fluoride membranes were visualized using a
super cooled-CCD camera system with a Davinch-K Gel
imaging system (Dvinch-K, Seoul, South Korea). The
density of each band was converted to numerical values
using NIH Image J program (http://rsbweb.nih.gov/ij/),
with the background values subtracted from an area of
film immediately adjacent to the stained band. Data are
expressed as the ratio of each value against GAPDH for
each sample. Experiments were repeated three times
with similar protocol.

Real-time polymerase chain reaction (PCR) analyses
Real-time PCR was accomplished using SYBR Green
PCR Master Mix (ABI, Warrington, UK) as described
previously described [20–22]. Reactions (n = 3 per
group) were performed in duplicate in a total vol-
ume of 10 μl containing 10 pM primer, 4 μl cDNA,
and 5 μl SYBR Green PCR Master Mix. The mRNA
levels of each target gene were normalized to that of
GAPDH mRNA. Fold-induction was calculated using
the 2−ΔΔCT method, as previously described [23]. All
real-time RT-PCR experiments were performed in
triplicates, repeated at least three times. The values
are presented as mean ± SEM values unless otherwise
noted. The primer sequences were as follows: monocyte
chemoattractant protein (MCP)-1, CTG TTC 3′ and
5′-CCA GCC TAC TCA TTA A-3′ and 5′-AGG CAT TCA
TTG GGA TCA-3′, macrophage inflammatory protein
(MIP)-1α, TTA CCG GAA GAT TAC ATT TCC CT-3′
and 5′-AGG CAT TCA GTT CCA GGT CA-3′, regu-
lated upon activation, normal T cell expressed and pre-
sumably secreted (RANTES)-5′-ACA CCA CCA CTT
GCT GTT TT-3′ and 5′-GAC TGC TAA GAA ATT GGA
GCA CTT GA-3′, CD3-5′-CTG GCT TGC TGA
TGG-3′ and 5′-GTT TGG GAA CAG GTG GTG-3′,
T-bet-5′-CGG AGG GAA CCA CCA ACA GCA TGG
TTT C-3′ and 5′-CAG GAT AGC CAT CCA CCG GCG
GTT-3′, interferon-gamma (IFN)-γ-5′-ACA ATG AAC
GCT ACA CAC TGC AT-3′ and 5′-TCG CAG TAA
CAG CCA GAA ACA-3′, ROR-γt-5′-GAC TCC GAG
ACC CAG A-3′ and 5′-TCC CAC ATC TCC CAC
ATT G-3′, interleukin (IL)-17A-5′-GTC GAT CAT GGC
TTG GTT GT-3′, transforming growth factor (TGF)-β-5′-GCC
CTG GAC AAC TAT TCG-3′ and 5′-GCA GGA GCG
CAC AAT CAT GTT-3′, GATA-3-5′-GAA GCC ATC
CAG ACC CGA AAC-3′ and 5′-ACC CAT GGC GGT
GAC CAT GC-3′, IL-4-5′-AGA ACA ACA CCA CAG
AGA GTG AGC T-3′ and 5′-GAC TCA TTC ATG ATG
CAG CTT ATC A-3′, occulin-5′-AGT CAT CTC TCC
GCC ATA CAT-3′ and 5′-AGA CCT GAT GAA TTC
AAA CCC AAT-3′, claudin-5-5′-AGG GCA GGC GCC
CTT TAC-3′ and 5′-GTT GCC GAA CCA GCA GAG-
3′, intercellular adhesion molecule (ICAM)-1-5′-TGC
GTT TTG GAG CTA GGC AGC CA-3′ and 5′-CGA
GGA CCA TAC AGC TGC AG-3′, vascular cell
adhesion molecule (VCAM)-1-5′-CCT CAC TTG
CAG CAC TAC GGG CT-3′ and 5′-TTT TCC AAT
ATC CTC AAT GAC GGG-3′, cyclooxygenase (COX)-
2-5′-CAG TAT CAG AAC AGC CGC ATT GCC-3′
and 5′-GAG CAA GTC GTT CCT TAA GGA-3′, iNOS-5′-
GGC AAA CCC AAG ATC TGC TAG GTT-3′ and 5′-TGC
CAG CTT GAG ATC TG-3′, tumor necrosis factor
(TNF)-α-5′-AGG TCA TCA GCT TCT TTA-3′ and
5′-GCT GCC GCC ACT ACT GTG TTG-3′, NAD(P)H:
quinone oxidoreductase (NOX)-1-5′-AGG TCG TGA
TTA CCA AGG TTG TC-3′ and 5′-AAG CCT CGC TTC
CTC ATC TG-3′, NOX2-5′-ACT CCT TGG GTC AGC
ACT GG-3′ and 5′-CTT CCT GTC CAG TAT TCG-3′,
NOX3-5′-GTT ATC ACAA GCC TTA AAG CAG GC-3′
and 5′-GCC CCT GTC AGC CAC-3′, NOX4-5′-GTT
AGG TCA TCA GCT TCT TTA-3′ and 5′-AAG CCT
AGC TTA AAG CAG GC-3′ and 5′-CCA CCT
TCC ACT TCA GTT TAG-3′, NOX4-5′-CCT
CAT GGT TAG AGC TTC TAC CTA CGC-3′ and 5′-
TGA TCA AGG TAC AGC TGG ATG TTC ATC-3′, and
GAPDH-5′-AGG TCA TCC CAG AGC TGA ACG-3′
and 5′-CAC CCT GTT GCT GTA GCC GTA T-3′.
Measurement of weights of spleen and lymph nodes

At the peak day (19–20 days after EAE\text{low} induction) of neurological disorder, 5 mice in each group were anesthetized. Their spleens and lymph nodes were carefully removed without fat, connective tissue, or fluid. They were weighed using a microbalance (OHAUS, Parsippany, USA). The experiment was repeated three times.

Flow cytometry

At the peak stage of neurological impairment (19–20 days after EAE\text{low} induction), 5 mice from each group were euthanized under brief diethyl ether anesthesia followed by perfusion with 0.9% physiological saline and then spleen and lumbar spinal cord were carefully cropped. To measure the level of cell population, single-cell suspensions refined from whole tissue were pre-cropped. To measure the level of cell population, single- and then spleen and lumbar spinal cord were carefully followed by perfusion with 0.9% physiological saline were euthanized under brief diethyl ether anesthesia.

Briefly, after acquiring unstained and single colored control samples to calculate compensation matrix, we acquired $1 \times 10^4$ events within the combined gate based on physical parameters [forward scatter (FSC) and side scatter (SSC)]. CD11b\textsuperscript{+}/CD45\textsuperscript{low} cells and CD11b\textsuperscript{+}/CD45\textsuperscript{high} cells were gated as resident microglia and macrophages, respectively. For intracellular cell analysis, cells were restimulated with phorbol-12-myristate-13-acetate and ionomycin and Golgistop in RPMI media. After 5 h, cells were stained with PerCP-Cy 5.5 anti-mouse CD4 (RM4-5; BD Biosciences), FITC anti-mouse IFN-γ (XMG1.2; BD Biosciences), PE anti-mouse t-bet (4B10; BD Biosciences), PE anti-mouse IL-17A (TC11-18H10; BD Biosciences), APC anti-mouse RORγt (B2D; eBioscience, NH, USA), PE anti-mouse IL-4 (11B11; BD Biosciences), PE anti-mouse CD25 (PC61.5; FJK-16 s; eBioscience), and APC anti-mouse/rat Foxp3 (FJK-16 s; eBioscience) for 30 min at 4 °C. The cells were washed twice with 2% fetal bovine serum in PBS and used for flow cytometry as described [20–22]. To identify CD4\textsuperscript{+} T cell populations, cells ($1 \times 10^4$) were first gated using FSC and SSC properties. CD4\textsuperscript{+} T cells were used to analyze populations of Th1 (CD4\textsuperscript{+}/IFN-γ\textsuperscript{+}/T-bet\textsuperscript{+}), Th17 (CD4\textsuperscript{+}/IL-17A\textsuperscript{+}/RORγt\textsuperscript{+}), Treg (CD4\textsuperscript{+}/CD25\textsuperscript{+}/Foxp3\textsuperscript{+}), and Th2 (CD4\textsuperscript{+}/IL-4\textsuperscript{+}) cells on CD4\textsuperscript{+} T cells (Fig. 4). Three-color staining of one cell was performed for simultaneous analysis. Intracellular cytokine levels were indicated as percentages within CD4\textsuperscript{+} population. Data were collected on a FACS Calibur flow cytometer (BD Biosciences) and analyzed using Cell Quest Pro software (BD Biosciences) described [20–22]. Experiments were repeated three times with same protocol.

Statistical analyses

Statistical analysis was performed using the SPSS 24.0 package (SPSS Inc, Chicago, USA) for Windows. Neurological scores obtained by EAE induction were analyzed using two-way analysis of variance (ANOVA) with repeated measures with one within-subjects factor (time) and two between-subject factors (Sham and EAE group; EAE and EAE + antagonist/or agonist group). The data from organ weight, immunohistochemistry, Western blot, flow cytometry, and real-time PCR analysis were performed using one-way ANOVA with Tukey post hoc test for comparison of multiple groups. The data were presented as mean ± SEM. $p$ values of less than 0.05 were accepted as statistically significant.

Results

Ki16425 deteriorates motor disability and spinal demyelination during EAE\text{low}

To examine whether Ki16425, LPAR 1–3 antagonist, might have a beneficial or detrimental effect on motor disability of EAE mice, mice were immunized with 200 µg of MOG peptide and 500 µg of Mtb (B). LPAR1–3 antagonist (A) or agonist (B) was i.p. injected once daily from onset phase (day 8–9 after EAE induction) of motor disability. Level of motor disability was then measured daily until the last day of the experiment. For various analyses, mice were euthanized at the peak day (19–20 days after EAE induction) of neurological symptoms.

Statistical analyses

Statistical analysis was performed using the SPSS 24.0 package (SPSS Inc, Chicago, USA) for Windows. Neurological scores obtained by EAE induction were analyzed using two-way analysis of variance (ANOVA) with repeated measures with one within-subjects factor (time) and two between-subject factors (Sham and EAE group; EAE and EAE + antagonist/or agonist group). The data from organ weight, immunohistochemistry, Western blot, flow cytometry, and real-time PCR analysis were performed using one-way ANOVA with Tukey post hoc test for comparison of multiple groups. The data were presented as mean ± SEM. $p$ values of less than 0.05 were accepted as statistically significant.

Results

Ki16425 deteriorates motor disability and spinal demyelination during EAE\text{low}

To examine whether Ki16425, LPAR 1–3 antagonist, might have a beneficial or detrimental effect on motor disability of EAE mice, mice were immunized with 200 µg of MOG peptide and 500 µg of Mtb (B). LPAR1–3 antagonist (A) or agonist (B) was i.p. injected once daily from onset phase (day 8–9 after EAE induction) of motor disability. Level of motor disability was then measured daily until the last day of the experiment. For various analyses, mice were euthanized at the peak day (19–20 days after EAE induction) of neurological symptoms.

Statistical analyses

Statistical analysis was performed using the SPSS 24.0 package (SPSS Inc, Chicago, USA) for Windows. Neurological scores obtained by EAE induction were analyzed using two-way analysis of variance (ANOVA) with repeated measures with one within-subjects factor (time) and two between-subject factors (Sham and EAE group; EAE and EAE + antagonist/or agonist group). The data from organ weight, immunohistochemistry, Western blot, flow cytometry, and real-time PCR analysis were performed using one-way ANOVA with Tukey post hoc test for comparison of multiple groups. The data were presented as mean ± SEM. $p$ values of less than 0.05 were accepted as statistically significant.

Results

Ki16425 deteriorates motor disability and spinal demyelination during EAE\text{low}

To examine whether Ki16425, LPAR 1–3 antagonist, might have a beneficial or detrimental effect on motor disability of EAE mice, mice were immunized with 200 µg of MOG peptide and 500 µg of Mtb (B). LPAR1–3 antagonist (A) or agonist (B) was i.p. injected once daily from onset phase (day 8–9 after EAE induction) of motor disability. Level of motor disability was then measured daily until the last day of the experiment. For various analyses, mice were euthanized at the peak day (19–20 days after EAE induction) of neurological symptoms.
MOG35–55 peptide to induce EAE with mild symptom (referred to as EAElow) and i.p. treated with Ki16425 at daily dose of 15 or 30 mg/kg or vehicle (5% DMSO/PBS) until the end of the experiment from the onset stage of symptom (day 9 after EAElow induction) (Fig. 1A). Mice in the EAElow group displayed mild motor disability (mean score, 1.31±0.2) from the onset stage. However, treatment with 30 mg/kg of Ki16425 significantly deteriorated motor disability of EAElow during the experimental period (Fig. 2A). From the onset day of motor disability to 19–20 days, maximum scores of motor disability (2.8±0.4) and cumulative scores of motor disability
(21.9 ± 1.8) in the 30 mg/kg Ki16425-treatment groups were significantly higher than those in the EAElow group (1.5 ± 0.3 and 14.4 ± 2.0, respectively) (Fig. 2A, B). Protein expression levels of LPAR1 in spinal cords of EAElow mice were slightly but not significantly enhanced than those in the sham group, whereas levels of LPAR3 were significantly increased. However, Ki16425 treatment reduced their protein expression levels in a dose-dependent manner (Fig. 2C, D). Since CNS demyelination is a typical histopathological feature of MS patients and EAElow model [25, 26], whether worsened motor disability after Ki16425 treatment might have a significant relation with the level of CNS demyelination was then investigated. The 30 mg/kg Ki16425 treatment conspicuously increased levels of spinal demyelination (pale portion in white matter) after staining white matters of spinal cords.
with LFB dye on day 19–20 following EAElow induction (Fig. 2E, F), in concordance with the pattern of results from MBP immunofluorescence staining (Fig. 2E right panel) and Western blot analyses (Fig. 2G). Additionally, we explored whether the withdrawal effect of Ki16425 might offset the deteriorating effect of Ki16425 in the same model. As expected, withdrawal of Ki16425 from day 18 after EAElow induction (the highest score of motor disability: 1.8 ± 0.3 in 15 mg/kg Ki16425 and 2.3 ± 0.2 in 30 mg/kg Ki16425) perfectly neutralized it detrimental effects for motor disability (lowest score of motor disability: 1.2 ± 0.1 in 15 and 30 mg/kg) (Fig. 2H).

Ki16425 enhances infiltration of immune cells such as CNS-resident microglia and blood-borne macrophages in the spinal cord of EAElow mice

To examine whether the deteriorated motor disability and spinal demyelination observed in Ki16425-treated EAElow mice might have a connection with alleviation in CNS inflammation, the level of cellular infiltration in the spinal cord was determined by H&E staining (Fig. 3). The level of cellular infiltration was slightly enhanced in the white matter of the spinal cord of the EAElow group compared to that of the sham group. However, this level was notably increased in 30 mg/kg Ki16425-treated EAElow group (Fig. 3A, B). Cellular infiltration into the CNS lesion site is known to be associated with an increase of chemokine expression [2, 3, 6]. Thus, mRNA expression levels of representative chemokines (MCP-1, MIP-1α, and RANTES) in the spinal cord at 19–20 days after EAElow induction were determined by real-time PCR analysis (Fig. 3C–E). 30 mg/kg Ki16425 treatment remarkably increased mRNA expression levels of MCP-1 (55. ± 25.6 folds), MIP-1α (14.1 ± 2.1 folds), and RANTES (377.7 ± 63.6 folds) in the spinal cord after EAElow induction compared to that of the sham (vehicle-treated EAElow) group (Fig. 3C–E).

Cellular infiltrates into CNS can include CNS-resident microglia, blood-borne macrophages, T cells, and so on. Therefore, whether Ki16425 treatment affected their infiltration into demyelinated lesion was determined by immunohistochemistry. 30 mg/kg Ki16425 treatment remarkably increased the level of Iba-1 immunoreactivity in the spinal cord following EAElow induction compared to that in the EAElow group (Fig. 3F), corresponding to the upregulated protein expression of Iba-1 as shown by Western blot analysis (Fig. 3G). Since Iba-1 antibody recognizes both microglia and macrophages [27], differentiating both cell types based on immunostaining and Western blot has a limitation. Thus, both cells were further characterized by flow cytometry (Fig. 3H, I). Upon immunization, the percentage of CD11b+/CD45+ (low) cells (R5 rectangle in Fig. 3H) representing resident microglia [20–22, 24] increased to 4.0 ± 0.2% in spinal cords of the EAElow group. Interestingly, this percentage was further increased to 7.7 ± 0.7% in spinal cords of Ki16425-treated group (Fig. 3H, I). The percentage of CD11b+/CD45+ (high) cells (R6 rectangle in Fig. 3H) representing macrophages [20–22, 24] was also increased to 0.9 ± 0.3% in spinal cords of EAElow group. By this way, this percentage was further increased to 3.8 ± 0.7% in spinal cords of Ki16425-treated group (Fig. 3H, I).

Ki16425 induces the hypertrophy of lymphatic organs and the CD4+ T cell infiltration in the spinal cords of EAElow mice

Secondary lymphoid organs such as spleen and lymph nodes might be hypertrophied in EAE murine model [28]. Thus, their weights were measured to compare their hypertrophy levels at 19–20 days following EAElow induction. Weights of spleen and lymph nodes were slightly increased in the EAElow group (0.32 ± 0.04 g and 0.12 ± 0.02 g, respectively), but they are not significant. However, their weights were further increased in the 30 mg/kg Ki16425-treated EAElow group (0.67 ± 0.11 g and 0.30 ± 0.04 g, respectively; Fig. 4A, B). Since recruitment and infiltration of autoreactive
Fig. 4 (See legend on previous page.)
Fig. 4 continued
T cells are major initiators and mediators of pathogenesis in MS and its animal models [1–3], the levels of T cell infiltration into spinal cords following EAE induction were measured by real-time PCR analysis, Western blot, and immunofluorescence stain for CD3, a marker for T cells [29]. The mRNA expression of CD3 was slightly enhanced in spinal cords of the EAElow group at 19–20 days after EAElow induction (5.8 ± 2.8 folds), whereas its expression level was more enhanced in spinal cords of 30 mg/kg Ki16425-treated EAElow group (62.5 ± 8.2-fold) (Fig. 4C). Protein expression levels of CD3 were also slightly upregulated in spinal cords of the EAElow group at 20 days after EAElow induction (15.6 ± 4.9%), whereas its expression levels were more upregulated in spinal cords of 30 mg/kg Ki16425-treated EAElow group (50.1 ± 0.5%) (Fig. 4D). Moreover, the expression pattern of CD3 immunoreactive cells (Fig. 4E, F) in agreement with mRNA (Fig. 4C) and protein expression patterns of CD3 (Fig. 4D). By flow cytometry analysis, the percentage of CD4+ T cells was also slightly enhanced in spinal cords (1.0 ± 0.2%) and spleen (24.4 ± 1.0%) following EAElow induction, but they are not significant. However, their increases were much more enhanced in the spinal cords (3.6 ± 0.7%) and spleen (30.7 ± 1.8%) of 30 mg/kg Ki16425-treated EAElow group (Fig. 4G–I). As expected, the percentage of cytotoxic CD8+ T cells was not significantly affected by EAElow induction or Ki16425 treatment (Fig. 4G–I).

**Ki16425 increases the percentages of Th1 and Th17 cells in the spinal cords of EAElow mice**

Naive CD4+ T cells are activated after interaction with antigen–major histocompatibility complex to differentiate into specific subtypes, such as Th1, Th2, Th17, and regulatory T (Treg) cells during T cell receptor (TCR) activation in a particular cytokine milieu, which are involved in autoimmunity and produce proinflammatory cytokines such as IFN-γ, IL-4, IL-17, and TGF-β, respectively [30, 31]. Therefore, subtypes of CD4+ T cells in spinal cord and spleen after EAElow induction were discriminated. In the EAElow group, percentages of Th1 (CD4+/IFN-γ+/T-bet+) cells was 1.1 ± 0.6% in the spinal cords and 28.6 ± 1.3% in the spleen. Interestingly, in the EAElow + 30 mg/kg Ki16425 group, their percentages were more increased to 2.0 ± 0.3% in spinal cords and to 41.8 ± 5.1% in the spleen (Fig. 4K–M), corresponding to the pattern of mRNA expression of IFN-γ (an interleukin produced by Th1 cells) and T-bet (a transcription factor of Th1 cells) in spinal cords (Fig. 4N, O). In the EAElow group, percentages of Th17 (CD4+/IL-17A+/RORγt+) cells was 6.9 ± 0.0% in the spinal cords and 9.1 ± 1.7% in the spleen. Interestingly, in the EAElow + 30 mg/kg Ki16425 group, percentages of Th17 cells was more enhanced to 10.3 ± 1.4% in spinal cords and to 25.9 ± 7.7% in the spleen (Fig. 4P–R). In concordance with these results, mRNA expression levels of IL-17A (an interleukin produced by Th17 cells) and RORγt (a transcription factor of Th17 cells) were conspicuously enhanced in spinal cords of Ki16425-treated EAElow group (Fig. 4S, T). However, percentages of Treg (CD4+/CD25+/Foxp3+) cells for maintaining tolerance to self-antigens and suppressing autoimmune responses were not significantly affected by EAElow induction with Ki16425 treatment (Fig. 4U–W), corresponding to the pattern of mRNA expression of Foxp3 (a transcription factor of Treg cells) and TGF-β (an interleukin produced by Treg cells) in spinal cords (Fig. 4X, Y). Also, the percentage of Th2 (CD4+/IL-4+) cells was not significantly altered after EAElow induction with Ki16425 treatment, in agreement with significantly unaltered mRNA expression levels of GATA3 (a transcription factor of Th2 cells) and IL-4 (an interleukin produced by Th2 cells) (Fig. 4Z–AD).

**Ki16425 stimulates BBB disruption in spinal cords of EAElow mice**

Disruption of the BBB is one of the major features in the progression of MS and EAE. Peripheral inflammatory cells and toxic molecules can migrate into the CNS via the damaged BBB, resulting in cerebral edema, demyelination, and neural cell death [4, 5]. Consequently, we examined whether Ki16425 was involved in the maintenance of BBB integrity on day 19–20 after EAElow induction. Levels of leakage of albumin and IgG by immunofluorescence staining were slightly increased in spinal cords of EAElow group than those in the sham group. Their levels were much more increased in spinal cords of mice in the 30 mg/kg Ki16425-treated EAElow groups (Fig. 5A–C). Protein expression levels of PECAM-1 (an important indicator of BBB dysfunction) and GFAP (a specific marker of astrocytes) were upregulated in spinal cords of EAElow group than those in the sham group. Their expression levels were much more increased in spinal cords of mice in the 30 mg/kg Ki16425-treated EAElow group (Fig. 5D, E). In accordance with these results, PECAM-1 and GFAP-positive immunofluorescence signals were also clearly enhanced in spinal cords of mice in the 30 mg/kg Ki16425-treated EAElow group (Fig. 5F). Tight junctions are specialized cell–cell adhesion structures and critical components of the BBB. They might be abnormally distributed in CNS tissues of MS patients and EAE mice [4, 5, 32–34]. Thus, we further investigated whether Ki16425 treatment exerted beneficial or detrimental effects on the expression of transmembrane molecules of tight junctions in spinal cords of mice on day 20 after EAElow induction by real-time PCR analysis (Fig. 5G, H). After treatment with
Fig. 5  Effect of Ki16425 on BBB disruption in spinal cords of EAE^{low} mice. A–K Lumbar spinal cords (n = 3 per group) were dissected from the sham, EAE^{low}, EAE^{low} + Ki16425 (15 and 30 mg/kg), and Ki16425 (30 mg/kg) groups at day 19–20 after immunization. A, F, and I Cryosections (n = 3 per spinal cord) were subjected to immunofluorescence staining with anti-albumin (upper panel in A), anti-IgG (lower panel in A), anti-PECAM-1 (upper panel in F), anti-GFAP (lower panel in F), anti-occludin (upper panel in I), or anti-claudin-5 antibody (lower panel in I). Their images were captured by confocal microscope and the levels of relative intensity were measured (B and C). D and E Lysates from lumbar spinal cords were analyzed by Western blot to investigate protein expression of PECAM-1 (D) and GFAP (E). G, H, J, and K The lysates (n = 3 per group) were analyzed by real-time PCR to measure the degrees of occludin (G) and claudin-5 (H) to represent tight junctions and ICAM-1 (J) and VCAM-1 (K) to represent cell adhesion molecules. Bar = 100 µm. Quantified data are expressed as mean protein level or fold induction ± SEM. (ANOVA test; #p < 0.05 versus sham group; *p < 0.05 and **p < 0.01 versus EAE^{low} group.
Ki16425 at 30 mg/kg, mRNA expression levels of occluding and claudin-5 in spinal cords of mice in the EAE<sub>low</sub> group were reduced (0.5-fold and 0.7-fold, respectively) compared to those in the sham group (1.0-fold) or the EAE<sub>low</sub> group (1.2-fold) (Fig. 5G, H). These results coincided with patterns of immunofluorescence expression of the occluding and claudin-5 (Fig. 5I). Since cellular adhesion molecules such as ICAM-1 and VCAM-1 are involved in the adhesion of peripheral inflammatory cells such as lymphocytes and macrophages to endothelial cells in lesion area during MS and EAE<sub>low</sub>, we investigated the effect of Ki16425 treatment on their expression by real-time PCR analysis (Fig. 5J, K). After Ki16425 treatment, mRNA expression levels of ICAM-1 and VCAM-1 in spinal cords after EAE<sub>low</sub> induction were significantly upregulated (15.3-fold and 1.8-fold, respectively) compared to those in the EAE<sub>low</sub> group (2.4-fold and 1.1-fold, respectively) (Fig. 5J, K).
Ki16425 induces proinflammatory cytokine milieu and oxidative stress in spinal cords after EAE\textsuperscript{low} induction

Since inflammation is critically involved in pathological mechanism underlying MS and EAE [35, 36], we tested the effect of Ki16425 on inflammatory response in spinal cords at day 19–20 after EAE\textsuperscript{low} induction (Fig. 6). The severity of inflammatory response was compared based on expression levels of COX-2, p-p38 MAPK, and p-NF-kB/p65 known as central mechanisms of inflammation. Expressions of COX-2, p-p38 MAPK, and p-NF-kB/p65 showed a quietly enhancing pattern in spinal cords of the EAE\textsuperscript{low} group (46.6%, 33.2%, and 32.1%, respectively) compared to those in the sham group (18.5%, 20.9%, and 13.0%, respectively). However, their expression levels were notably enhanced by 30 mg/kg Ki16425 treatment (99.4%, 110.4%, and 61.7%, respectively) compared to vehicle treatment (Fig. 6A–C). In accordance with these results, mRNA expression levels of representative inflammatory enzymes COX-2 and iNOS and a representative proinflammatory cytokine TNF-α were also significantly increased by 30 mg/kg Ki16425 treatment (Fig. 6D–F). Ki16425 itself did not significantly regulate the expression of inflammatory enzymes or proinflammatory cytokine and the phosphorylation of p38 MAPK and NF-kB pathways (Fig. 6A–F).

Excessive oxidative stress plays a critical role in various inflammatory mechanisms underlying MS and EAE [7, 9, 37, 38]. Thus, we tested the effect of Ki16425 on oxidative stress in the spinal cords of mice on day 19–20 after EAE\textsuperscript{low} induction (Fig. 6G–M). The level of oxidative stress was measured with 4-hydroxynonenal (4-HNE) widely accepted as a stable marker for oxidative stress [39]. Protein expression levels of 4-HNE was in slightly increasing pattern in spinal cords of the EAE\textsuperscript{low} group (31.0%) compared to those in the sham group (8.8%), while they were strikingly upregulated in 30 mg/kg Ki16425-treated EAE\textsuperscript{low} group (102.1%) (Fig. 6G). Mitochondrial superoxide level was also analyzed by MitoSOX\textsuperscript{TM} Red assay. The median fluorescence intensity was significantly increased in spinal cords of the EAE\textsuperscript{low} group (0.9 cells/μm\textsuperscript{2}) compared to that in the sham group (0.4 cells/μm\textsuperscript{2}). However, the intensity was much more increased after Ki16425 treatment (3.7 cells/μm\textsuperscript{2}) (Fig. 6H, I). Oxidation status (ROS level) in the spinal cord was determined based on NADPH oxidase (NOX) expression and NADPH activity. Although mRNA levels of NOX1–3 were not significantly changed in spinal cords after treatment with Ki16425 compared to those in the EAE\textsuperscript{low} group without such treatment, mRNA levels of NOX2 and NOX3 were significantly increased by treatment with Ki16425 at 15 or 30 mg/kg compared to those in the EAE\textsuperscript{low} group without such treatment (Fig. 6J–L). In spinal cords of the EAE\textsuperscript{low} group without treatment with Ki6425, NOX4 mRNA levels were significantly enhanced. However, NOX4 mRNA levels were not significantly altered by Ki16425 treatment (Fig. 6M).

These results indicate that Ki16425 treatment might deteriorate EAE by activating NOX2/3 signaling.

LPAR1/2 agonist, 1-oleoyl-LPA, mitigates motor disability and main pathological features of EAE\textsuperscript{high} mice

In the current study, LPAR1–3 antagonist, Ki16425, remarkably worsened motor disability of EAE\textsuperscript{low} mice (Fig. 2A, B), in accordance with increased demyelination (Fig. 2E–G), enhanced inflammatory response (Figs. 3, 4, and 6), amplified ROS pathway (Fig. 6), and worsened BBB integrity (Fig. 5) in spinal cords after EAE\textsuperscript{low} induction. These findings suggest that activating the LPA signaling pathway might have beneficial effects on EAE\textsuperscript{low}. To demonstrate this possibility, 1-oleoyl-LPA, a LPAR1/2 agonist, was i.p. injected to mice for 10 days from the onset stage of EAE\textsuperscript{high} symptom (day 8 after EAE\textsuperscript{high} induction with a mean score of 0.5±0.2). As expected, 1-oleoyl-LPA mitigated motor disability of EAE\textsuperscript{high} (Fig. 7A, B) along with a reduction of demyelination (Fig. 7C upper panel and D), cellular infiltration (Fig. 7C middle panel), microglial activation (Fig. 7C lower panel and E), expression of a representative inflammatory enzyme COX-2 (Fig. 7F), protein expression of a representative BBB marker PECAM-1 (Fig. 7G), protein expression of a representative oxidative stress marker 4-HNE (Fig. 7H), and mRNA expression of NOX2 and NOX3 (Fig. 7I, J). Treatment with 1-oleoyl-LPA also enhanced protein expression levels of LPAR1 and LPAR2, but not LPAR3 in spinal cord of EAE\textsuperscript{high} group. In addition, protein expression levels of LPAR1, LPAR2, and LPAR3 were enhanced in the spinal cords of the EAE\textsuperscript{high} group compared to those in the sham group (Fig. 7K–M).
Fig. 7 (See legend on previous page.)
These results suggest that motor disability and main pathological events of EAE$^{high}$ mice can be neutralized by pre-stimulating the LPAR signaling pathway with LPAR1/2 agonist.

**Discussion**

Here, we demonstrated that antagonizing LPAR 1–3 with Ki16425 deteriorated specific motor disability and spinal demyelination after EAE induction, corresponding to increased cellular infiltrates (such as microglia, macrophage, Th1, and Th17 cells) and worsened BBB integrity. The mechanism underlying the deteriorated EAE was excessive oxidative stress via NOX2 and NOX3. Interestingly, LPAR1/2 agonist 1-oleoyl-LPA improved neurological symptoms and representative pathophysiological characteristics of EAE. These results provide new mechanistic insights into how LPA 1–3 signaling contributes to EAE pathophysiology. Taken together, our findings suggest that agents that can regulate LPAR 1–3 might be used as therapeutics for treating MS.

LPARs are differentially expressed on most cell types within central and peripheral nervous tissues. They preferentially bind to saturated, monounsaturated, and polyunsaturated LPAs [14]. Signal transduction through LPARs has been functionally linked to many neural processes, including cell proliferation, cell survival, apoptosis, morphological change, cell migration, and the production of other lipids such as prostaglandins through arachidonic acid conversion by cyclooxygenase-2 [14]. Therefore, LPARs have been considered as novel targets in lipidomic-based therapeutics for neurological disorders [16]. Many neurological disorders frequently accompany demyelination-associated signs and symptoms such as neuropathic pain, demyelinating neuropathies, and MS [20–22]. Loss of LPAR1 can impair oligodendrocyte differentiation and myelination due to impaired intracellular transport of the proteolipid protein (PLP)/DM20 myelin protein in the mouse cerebral cortex [40]. LPA1-null mutant mice have shown delayed Schwann cell-to-axon segregation, polyaxonal myelination by single Schwann cell, and thinner myelin sheaths via heterotrimeric G-alpha protein, Gz1, and small GTPase, Rac1 signaling [15]. LPA2-deficient mice have shown enhanced motor skills and myelin sparing after spinal cord injury related to oligodendrocyte cell death by activating microglial LPA2 [41]. LPA signaling is involved in various neurological diseases such as Alzheimer’s disease and traumatic brain injury [42, 43]. In traumatic brain injury, LPA activity is increased due to upregulated expression of LPAR1, LPAR2, and LPAR [42, 43]. In this study, protein expression levels of LPAR1–3 were increased in spinal cords of EAE$^{low}$ and EAE$^{high}$ mice (Figs. 2 and 7). Such an increase of LPA activity seems to be involved in early pathologic processes such as neurite retraction, reactive gliosis, inflammation, and cell death after trauma [42]. These reports strongly suggest that investigating new signaling mechanisms in these disorders might be critical in the development of therapeutics to stimulate spontaneous remyelination and subsequent functional recovery. In the present study, treatment with Ki16425, an LPAR1–3 antagonist, impaired motor disability and spinal demyelination after EAE$^{low}$ induction (Figs. 2 and 3), whereas treatment with 1-oleoyl-LPA, an LPAR1/2 agonist, mitigated them after EAE$^{high}$ induction (Fig. 7). These results indicate that LPA signaling via LPARs, specifically LPAR 1–3, might play a pivotal role in MS pathology.

Levels of resident microglia activation and infiltration of monocyte-derived immune cells to the CNS are associated with neurodegeneration in both MS and EAE [4]. Infiltrated immune cells are important contributors to the local chemical environment, releasing either anti-inflammatory growth factors or proinflammatory cytokines depending on their activation states. However, whether they have beneficial or detrimental roles remains controversial [4]. BV-2 cells express LPAR 2, 3, 5, and 6, whereas primary murine microglia express LPAR 1, 2, 4, 5, and 6 [44]. It has been shown that LPAR1 knockdown in the brain with its specific shRNA lentivirus can attenuate sepsis-induced microglia activation, morphologi cal transformation, and proliferation, in agreement with the downregulation of TNF-α production by activating ERK1/2 in the brain and LPS-stimulated cells [45]. On the other hand, LPAR1–3 antagonist, Ki16425, reduced numbers and soma sizes of activated microglia. It also reduced microglial proliferation, in correspondence with reduced mRNA expression levels of proinflammatory cytokines and suppressed NF-κB activation in the ischemic brain. Particularly, these LPAR1-derived proinflammatory responses have appeared in activated microglia because NF-κB activation occurs mainly in activated microglia [46]. LPAR2 is constitutively expressed in the spinal cord parenchyma. Its transcripts are upregulated after spinal cord injury, in part, by microglial cells [41]. The demyelinating lesion triggered by intraspinal injection of LPA into the undamaged spinal cord was markedly reduced in the absence of LPAR2 [41]. LPAR2-deficient mice have shown enhanced locomotor skills and myelin sparing after spinal cord injury [41]. Thus, these previous reports suggest that LPAR1–3 has a novel function in microglial activation and that its mechanism could be involved in the pathogenesis of diverse neurological diseases related to microglial activation. Our previous study has shown that gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, can reduce 3-nitropropionic acid-induced striatal toxicity through its antioxidant and
anti-inflammatory activities. It downregulated microglial activation through LPA, whereas LPAR1–3 antagonist, Ki16425, neutralized gintonin’s beneficial effects [47]. In the present study, LPAR 1–3 antagonist, Ki16425, also increased microglial activation and infiltration of peripheral immune cells (macrophages) to demyelinating lesion following EAE induction (Figs. 2, 3, 4, 5 and 6), whereas LPAR 1/2 agonist inhibited them after EAEhigh induction (Fig. 7). Our findings suggest that LPAR 1–3 might play a critical role in the EAE pathology via microglial activation and peripheral immune cell infiltration into lesion.

During MS and EAE process, naïve T cells primed by antigen presenting cells such as microglia, macrophages, and dendritic cells can differentiate into Th1, Th2, Th17, or Treg cells depending on the cytokine environment [30]. Up to now, the role of LPA signaling in T cell differentiation is clearly unknown. In the current study, mild EAE did not significantly change the size of the spleen and the lymph nodes, the population (number) of CD4 cells or its major subsets, or the population of CD8 T cells in the spleen following EAElow induction (Fig. 4). However, LPAR1–3 antagonist, Ki16425, clearly increased the size of the spleen and the lymph nodes and the population of CD4, Th1, and Th17 cells in the spleen associated with deteriorated EAElow symptoms and pathological features. However, LPAR1–3 antagonist did not significantly influence the population of CD8, Th2, or Treg cells in the spleen (Fig. 4). In the MS and EAE, peripheral autoreactive T cells can migrate across the disrupted BBB, attack myelin antigens, and induce demyelination in the CNS [5]. Although the migration of autoreactive T cells is mediated by multi-step process of lymphocyte diapedesis through the BBB [5, 30], the role of LPA signaling in the process is largely unknown. LPA and LPA-generating enzyme autotaxin are constitutively expressed at high endothelial venules of lymph nodes. They are implicated in lymphocyte trafficking and the regulation of lymphocyte entry into lymph nodes [48]. LPA signaling mediates the recruitment of leukocytes including CD3 T cells into unprimed and TNF-α-primed air pouches in a murine air pouch model of inflammation [49]. LPAR5 is an inhibitory receptor that suppresses CD8 T cell cytotoxic function via disruption of early TCR signaling [50]. These reports strongly suggest that LPA signaling might have a critical role in T cell migration into demyelinating lesion of EAE. In the present study, mild EAE did not significantly increase the population of CD3+ T cell or major subsets of CD4 T cell in the spinal cord after EAElow induction (Fig. 4). LPAR1–3 antagonist Ki16425 clearly increased the population of CD3 (T), CD4 (Th), Th1, and Th17 cells in the spinal cord associated with deteriorated EAElow symptoms and pathological features (Fig. 4). However, LPAR1–3 antagonist Ki16425 did not significantly influence the population of CD8 (Tc), Th2, or Treg cells (Fig. 4). Such detrimental effect of LPAR1–3 antagonist Ki16425 could be supported by a previous similar report showing that LPAR2-deficiency mice induced more T’ cells trafficked from the spleen to the spinal cord, leading to a defect in lymphocyte homing which was reflected by impaired clinical scores and stronger activation of microglia in the grey matter of spinal cords of EAE mice [18]. Taken together, our findings suggest that LPA signaling via LPAR1–3 might have pivotal role in T cell differentiation in the secondary lymphatic organs and T cell migration into CNS after EAE induction.

The BBB consists of endothelial cells, pericytes, basal membrane, and foot process of astrocytes. It acts as structural and functional barrier to the crossing of peripheral immune cells (macrophages and T cells) into the CNS in vivo or cultured astrocytes expressing Lpar1–5 [51, 52]. The LPA1–3 antagonist Ki16425 has abolished LPA-induced vasorelaxation [53]. Cultured endothelial cells are known to express LPAR1–6 [54, 55]. LPA signaling can promote the survival and proliferation of endothelial cells from a variety of sources [56], including brain microvascular bEND.3 cells [54]. These reports suggest that LPAR antagonist might exert a negative effect on BBB maintenance. Here, we investigated the effect of LPAR1–3 antagonist Ki16425 on BBB integrity and permeability. LPAR1–3 antagonist Ki16425 enhanced levels of leakage of albumin and IgG by immunofluorescence staining in spinal cords of EAElow mice (Fig. 5). And Ki16425 upregulated protein expression levels of GFAP and PECAM as well as mRNA expression levels of ICAM-1 and VCAM-1 in spinal cords of EAElow mice (Fig. 5), in agreement with impaired motor disability of EAElow (Fig. 2). These results suggest that LPAR1–3 antagonist, Ki16425, might deteriorate EAE symptom associated with impaired BBB disruption caused by excessive astrocytic activation and increased expression levels of ICAM-1 and VCAM-1 in the spinal cord (Fig. 5).

Pathologically, NOX produces an excessive amount of ROS including hydrogen peroxide (H2O2), superoxide (O2−), and hydroxyl (OH•) radicals [9]. NOX2, NOX3, and NOX4 are the most prominently expressed NOX isotypes in the CNS. However, cellular and temporal expression profiles of these isotypes in injured and non-injured CNS are currently unclear [57]. In the MS and EAE, excessive ROS production overwhelms antioxidant defenses and induces oxidative damage (e.g., lipid peroxidation, protein nitration) in endothelial cells of the BBB and the myelin sheath, thereby propagating neurodegeneration [7, 8]. Activated microglia and infiltrated macrophages are responsible for ROS production in CNS lesions through upregulation of
NOX2 [7, 8]. Isolated microglia from NOX2 knock-out mice show reduced oxidative stress-induced toxicity to oligodendrocytes. In addition, the mice are more resistant to EAE [9]. NOX3 is expressed in neurons in the inner ear. Reduction of NOX3 exerts a protective effect in cochlear injury by reducing the level of oxidative stress [9]. On the other hand, LPAR1 inhibitor AM095 treatment inhibits LPA-induced ROS production and NOX expression as well as LPA-induced toll-like receptor 4 expression in mesangial cells and in the kidney of streptozotocin-induced diabetic mice [58]. In addition, AM095 treatment suppressed LPA-induced proinflammatory cytokines through downregulation of phosphorylated NF-κBp65 and c-Jun N-terminal kinases in vitro and in the kidney of streptozotocin-induced diabetic mice [58]. LPA signaling through LPAR3 increased expression levels of antioxidant enzymes, consequently inhibiting ROS accumulation and ameliorating cell senescence. Moreover, in a zebrafish model, LPA3 deficiency was sufficient to cause premature aging phenotypes in multiple organs as well as a shorter lifespan [59]. These results suggest that LPA or LPAR subtypes might exert significant positive or detrimental effects on neurodegeneration. Thus, we investigated the effect of LPAR1–3 antagonist, Ki16425, on oxidative stress after EAE<sub>low</sub> induction in the present study. LPAR1–3 antagonist Ki16425 significantly increased protein expression levels of 4-HNE, mRNA expression levels of NOX2 and NOX3, and NADPH activities in spinal cords of EAE<sub>low</sub> mice compared to those in the EAE<sub>low</sub> group associated with the enhanced microglial activation and the increased microphage infiltration (Figs. 2, 3, 4, 5, and 6). However, LPAR1/2 agonist 1-oleoyl-LPA significantly inhibited expression levels of ROS-associated markers in spinal cords of EAE<sub>high</sub> mice (Fig. 7). These results indicate that LPAR1–3 antagonist, Ki16425, may induce oxidative stress via activation of NOX2 and NOX3 and that oxidative stress might lead to deterioration of EAE symptoms. Taken together, our findings indicate that regulation of NOX2 and NOX3 via LPAR 1–3 is a key contributor to MS and EAE.

**Conclusions**
Ki16425, an antagonist of LPAR1–3, worsened EAE symptoms along with enhanced demyelination, inflammation, cellular infiltration, and BBB disruption caused by overproduction of ROS via NOX2 and NOX3, whereas 1-oleoyl-LPA, an agonist of LPAR1/2, alleviated them. These results suggest that functional activity of LPA signaling through LPAR1–3 might contribute to the pathophysiology of MS. Thus LPAR1–3 signaling might be a target to develop specific treatment for MS.

**Abbreviations**
4-HNE: 4-Hydroxynonenal; BBB: Blood–brain barrier; CNS: Central nervous system; COX-2: Cyclooxygenase-2; EAE: Experimental autoimmune encephalomyelitis; FITC: Fluorescein-isothiocyanate; FSC: Forward scatter; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; GFAP: Glial fibrillary acidic protein; H&E: Hematoxylin and eosin; iBA-1: Ionized calcium binding adaptor molecule-1; ICAM-1: Intercellular adhesion molecule-1; IFN-γ: Interferon-gamma; IL: Interleukin; LFB: Luxol fast blue; LPARs: Lysophosphatidic acid receptors; MBP: Myelin basic protein; MS: Multiple sclerosis; NADPH: Nicotinamide adenine dinucleotide phosphate; NOX: NADPH oxidases; PECAM-1: Platelet endothelial cell adhesion molecule-1; NF-κB: Nuclear factor-kappa B; MCP-1: Monocyte chemoattractant protein-1; MIP-1α: Macrophage inflammatory protein-1α; RANTES: Regulated upon activation, normal T cell expressed and presumably secreted; ROS: Reactive oxygen species; SSC: Side scatter; TGF-β: Transforming growth factor-β; TNF-α: Tumor necrosis factor-α; Treg: Regulatory T; VCAM-1: Vascular cell adhesion molecule-1.

**Acknowledgements**
Not applicable.

**Authors’ contributions**
JHC performed the evaluation of motor impairment, immunohistochemistry, PCR, flow cytometry, Western blot analysis, and prepared figures. JO assisted with flow cytometry analysis and the evaluation of motor impairment. JO assisted with flow cytometry analysis and the evaluation of motor impairment. HB contributed to flow cytometry analysis. MUL, SGK, and SYN contributed to the final version of the manuscript. IHC conceived all experiments, analyzed the results, and wrote the manuscript. All authors read and approved the final manuscript.

**Funding**
This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (NRF-2017R1A2A2A05069493, NRF-2016M3C7A1905074, NRF-2021R1H1A2010055, and NRF-2020R1A5A2019413).

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article and its additional files.

**Declarations**

**Ethics approval and consent to participate**
Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Kyung Hee University (KHUASP-18-174). Animal treatment and maintenance were carried out in accordance with IACUC guidelines. In this process, proper randomization of laboratory animals and handling of data were performed in a blinded manner in accordance with recent recommendations from an NIH workshop on preclinical models of neurological diseases [19].

**Consent for publication**
Not applicable.

**Completing interests**
All the authors of this manuscript have no conflict of interest in this subject.

**Author details**
1Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea. 2Department of Physiology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea. 3Korean Medicine-Based Drug Repositioning Cancer Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea. 4Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine and Bio/Molecular Informatics Center, Konkuk University, Seoul 05029, Republic of Korea.
of Korea. Institute of Convergence Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.

Received: 5 November 2020   Accepted: 20 September 2021

References

1. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15:545–56.
2. Mahdavian S, Dike U, Bryant A, Davison C, Ghazvini P, Hill A. Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments. J Pharm Pract. 2010;23:91–100.
3. Avisa PP, Hafier DA. Multiple sclerosis: genetics, biomarkers, treatments. Curr Opin Neurol. 2016;29:345–353.
4. Alshar B, KhalifehZadeh-Esfahani Z, Sefyzadeh N, Rezaei Danbaran G, Hemmatzadeh M, Mohammadi H. The role of immune regulatory molecules in multiple sclerosis. J Neuroimmunol. 2019;337:577061.
5. Ortiz GG, Pacheco-Moses FP, Macias-Islas MA, Flores-Alvarado LJ, Mireles-Ramirez MA, Gonzalez-Renovato ED, et al. Role of the blood-brain barrier in multiple sclerosis. Arch Med Res. 2014;45:687–97.
6. Finkelstein A. Multiple sclerosis: overview of disease-modifying agents. Perspect Med Chem. 2014;6:65–72.
7. Adaczyck B, Adaczyck-Sowa M. New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxid Med Cell Longev. 2016;2016:1973834.
8. Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, et al. Oxidative stress in neurodegenerative diseases. Mol Neurobiol. 2016;53:4094–425.
9. Ma KW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener. 2017;12:7.
10. Kang S, Han J, Song SY, Kim WS, Shin S, Kim JH, et al. Lysophosphatidic acid increases the proliferation and migration of adipose derived stem cells via the generation of reactive oxygen species. Mol Med Rep. 2015;12:5203–10.
11. Lin CC, Lin CE, Lin VC, Ju TK, Huang YL, Lee MS, et al. Lysophosphatidic acid induces reactive oxygen species generation by activating protein kinase C in PC-3 human prostate cancer cells. Biochem Biophys Res Commun. 2013;440:564–9.
12. Saunders JA, Rogers LC, Klomseri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med. 2010;49:2058–67.
13. Chang CL, Lin ME, Hsu HY, Yao CL, Hwang SM, Pan CY, et al. Lysophosphatic acid-induced interleukin-1 beta expression is mediated through Gi/Rho and the generation of reactive oxygen species in macrophages. J Biomed Sci. 2008;15:357–63.
14. Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic acid signaling in the nervous system. Neuron. 2015;85:669–82.
15. Anilkir B, Choi JW, Lin ME, Gardell SE, Rivera RR, Kennedy G, et al. Lysophosphatidic acid (LPA) and its receptor, LPA1, influence embryonic schwann cell migration, myelination, and cell-to-axon segregation. Glia. 2013;61:2009–22.
16. Choi JW, Chun J. Lysophospholipids and their receptors in the central nervous system. Biochim Biophys Acta. 2013;1831:20–32.
17. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 2010;50:157–86.
18. Schmitz K, Brunkhorst R, de Bruin N, Mayer CA, Hausler A, Ferreiros N, et al. Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmunne encephalomyelitis. Acta Neuropathol Commun. 2017;5:42.
19. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187–91.
20. Lee MJ, Bing SJ, Choi J, Jang M, Lee G, Lee H, et al. IKKbeta-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1 and Th17 responses. Mol Neurobiol. 2016;53:1419–45.
21. Lee MJ, Bing SJ, Choi J, Jang M, Lee G, Lee H, et al. IKKbeta-mediated inflammatory myeloid cell activation exacerbates experimental autoimmune encephalomyelitis by potentiating Th1 and Th17 cell activation and compromising blood brain barrier. Mol Neurodegener. 2016;11:54.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta Delta C(T)) Method. Methods. 2001;25:402–8.
23. Sedgwick JD, Schwender S, Imrich H, Dooris R, Butcher GW, ter Meulen V. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc Natl Acad Sci USA. 1991;88:7438–42.
24. Constantinescu CS, Faroqui N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol. 2011;164:1079–106.
25. Burrows DJ, McGowan A, Jain SA, De Felice M, Ramesh TM, Sharrack B, et al. Animal models of multiple sclerosis: from rodents to zebrafish. Mult Scler. 2015;25:306–24.
26. Ohawka K, Imai Y, Sasaki Y, Kohsaka S. Microglia/macrophage-specific protein lba1 binds to fimbirin and enhances its actin-bundling activity. J Neurochem. 2004;88:844–56.
27. Nam Y, Kim JM, Seo M, Kim JH, Jin M, Jeon S, et al. Lysophosphatidic acid (LPA) receptor type 2 (LPA2) protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues. J Biol Chem. 2014;289:16773–89.
28. Dong DJ, Zheng L, Lin J, Zhang B, Zhu Y, Li N, et al. Structural basis of assembly of the human T cell receptor-C3D complex. Nature. 2019;573:546–52.
29. Dittel BN. CD4 T cells: Balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain Behav Immun. 2008;22:421–30.
30. Waisman A, Johann L. Antigen-presentation cell diversity for T cell reactivation in central nervous system autoimmunity. J Mol Med (Berl). 2019;97:1279–92.
31. Brambilla R. The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol. 2019;137:757–83.
32. Lecuyer MA, Kebré H, Prat A. Glial Influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta. 2016;1862(3):472–82.
33. Alvarez JJ, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta. 2011;1812:252–64.
34. Mc Guire C, Prinz M, Beyaert R, van Loo G. Nuclear factor kappaB (NF-kappaB) in multiple sclerosis pathology. Trends Mol Med. 2013;19:604–13.
35. Krementsov DN, Thornton TM, Teuscher C, Rincon M. The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models. Mol Cell Biol. 2013;33:3728–34.
36. Radduch H, Bremer D, Guenther R, Ceeresnyezes Y, Lindquist R, Hauser AE, et al. Ongoing oxidative stress causes subclinical neurological dysfunction in the recovery phase of EAE. Front Immunol. 2016;7:92.
37. Ravelli KG, Santos GD, Dos Santos NB, Munhoz CD, Azzi-Nogueira D, Campos AC, et al. Nox2-dependent neuroinflammation in an EAE model of multiple sclerosis. Transl Neurosci. 2019;10:1–9.
38. Breitziog C, Brhiminen C, Lockey R, Kolluputi N. N-Hydroxy-2-nonenal: a critical target in oxidative stress? Am J Physiol Cell Physiol. 2016;311:C537–43.
39. Garcia-Diaz B, Riquelme R, Varela-Nieto J, Jimenez AJ, de Diego I, Gomez-Conde AI, et al. Loss of lysophosphatidic acid receptor LPA1 alters oligodendrocyte differentiation and myelination in the mouse cerebral cortex. Brain Struct Funct. 2015;220:3701–20.
40. Lopez-Serrano C, Santos-Nogueira E, Francos-Quijorna I, Coll-Mino M, Chun J, Lopez-Vales R. Lysophosphatidic acid receptor type 2 activation contributes to secondary damage after spinal cord injury in mice. Brain Behav Immun. 2019;76:258–67.
41. Geraldo LH,M, Spohr T, Amaaral RFD, Fonseca A, Garcia C, Mendes FA, et al. Role of lysophosphatidic acid and its receptors in health and disease: novel therapeutic strategies. Signal Transduct Target Ther. 2021;6:45.
42. Stoddard NC, Chun J. Promising pharmacological directions in the world of lysophosphatidic acid signaling. Biomol Ther (Seoul). 2015;23:1–11.
43. Plastira I, Berlamert E, Goentzer M, Reicher H, Kumble VB, Kogelnik N, et al. 1-Oleyl-lysophosphatic acid (LPA) promotes polarization of BV-2 and...
primary murine microglia towards an M1-like phenotype. J Neuroinflamm. 2016;13:205.
45. Kwon JH, Gaire BP, Park SJ, Shin DY, Choi JW. Identifying lysophosphatidic acid receptor subtype 1 (LPA1) as a novel factor to modulate microglial activation and their TNF-alpha production by activating ERK1/2. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:1237–45.
46. Gaire BP, Sapkota A, Song MR, Choi JW. Lysophosphatidic acid receptor 1 (LPA1) plays critical roles in microglial activation and brain damage after transient focal cerebral ischemia. J Neuroinflamm. 2019;16:170.
47. Jang M, Choi JH, Chang Y, Lee SJ, Nah SY, Cho IH. Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington’s disease: activation of the Nrl2 pathway through lysophosphatidic acid receptors. Brain Behav Immun. 2019;80:146–62.
48. Kanda H, Newton R, Klein R, Monta Y, Gunn MD, Rosen SD. Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs. Nat Immunol. 2008;9:415–23.
49. Hui W, Zhao C, Bourgoin SG. LPA promotes T cell recruitment through synthesis of CXCL13. Mediat Inflamm. 2015;2015:248492.
50. Mathew D, Kremer KN, Strauch P, Tigyi G, Pelanda R, Torres RM. LPAS is an inhibitory receptor that suppresses C08T-cell cytotoxic function via disruption of early TCR signaling. Front Immunol. 2019;10:1159.
51. Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol. 2003;64:1199–209.
52. Shano S, Moriyama R, Chun J, Fukushima N. Lysophosphatidic acid stimulates astrocyte proliferation through LPA1. Neurochem Int. 2008;52:216–20.
53. Ruisanchez E, Dansc P, Korek M, Nemeth T, Farago B, Balogh A, et al. Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase. FASEB J. 2014;28:880–90.
54. Schleicher SM, Thotoush DK, Linkous AG, Hu R, Leahy KM, Yazykovitskaya EM, et al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE. 2011;6:e22182.
55. Ren Y, Guo L, Tang X, Appasundaram S, Kitson C, Deguzman J, et al. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells. Microvasc Res. 2013;85:59–67.
56. English D, Kovala AT, Welch Z, Harvey KA, Siddiqui RA, Brindley DN, et al. Induction of endothelial cell chemotaxis by sphingosine 1-phosphate and stabilization of endothelial monolayer barrier function by lysophosphatidic acid, potential mediators of hematopoietic angiogenesis. J Hematother Stem Cell Res. 1999;8:627–34.
57. Cooney SJ, Bermudez-Sabogal SL, Byrnes KR. Cellular and temporal expression of NADPH oxidase (NOX) isotypes after brain injury. J Neuroinflamm. 2013;10:155.
58. Lee JH, Sarker MK, Choi H, Shin D, Kim D, Jun HS. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-kappaB signaling and NADPH oxidase. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1332–40.
59. Chen WM, Chiang JC, Lin YC, Lin YN, Chuang PY, Chang YC, et al. Lysophosphatidic acid receptor LPA3 prevents oxidative stress and cellular senescence in Hutchinson-Gilford progeria syndrome. Aging Cell. 2020;19:e13064.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.